Navigation Links
Novavax Announces Early Retirement of $17 Million of Convertible Debt
Date:4/29/2009

nt vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.

Forward Looking Statement

Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
2. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
3. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
4. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
5. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
6. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
7. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
8. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
9. Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009
10. NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate
11. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2015)... -- PureTech, a science-driven healthcare company seeking to solve some ... today that Dame Marjorie Scardino , Chairman of ... been appointed to PureTech,s Board of Directors in the ... member Joi Ito , MIT Media Lab,s Director, ... , PureTech,s outgoing Chairman and co-founder, former Executive Vice ...
(Date:5/22/2015)... , May 22, 2015 According ... Product (1D & 2D Gel Electrophoresis, Agarose & Polyacrylamide ... Reagents, Informatics), by Application & by End User - ... Market is expected to reach around $1.98 Billion by ... period 2015 to 2020. Browse 226 ...
(Date:5/21/2015)... St. Louis, MO (PRWEB) May 21, 2015 ... that assesses the safety and efficacy of pharmaceutical products ... Access Drive Maryland Heights, MO 63043, a 50,000 sq. ... their current location, to enable strategic growth. Facility renovations ... offices to the new space will occur in September. ...
(Date:5/21/2015)... 2015  The EveryLife Foundation for Rare Diseases ... Amy Klobuchar (D-MN) today for introducing ... Treatments, or OPEN ACT. Supported by ... this bipartisan legislation promises to rapidly bring hundreds ... disease patients by incentivizing drug makers to "repurpose" ...
Breaking Biology Technology:PureTech Adds Dame Marjorie Scardino to Board of Directors, Names Joi Ito as Chairman of the Board and Expands Management Team 2PureTech Adds Dame Marjorie Scardino to Board of Directors, Names Joi Ito as Chairman of the Board and Expands Management Team 3Electrophoresis Market Worth $1.98 Billion by 2020 2Electrophoresis Market Worth $1.98 Billion by 2020 3Electrophoresis Market Worth $1.98 Billion by 2020 4Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 3Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2
... CRANBURY, N.J., April 24 Amicus Therapeutics,Inc. (Nasdaq: ... and,Chief Executive Officer, will present a corporate update at ... 30,2008, at 2:20 p.m. EDT, at the Ritz-Carlton in ... live and may be accessed by visiting,Amicus, website at ...
... announced it will release its fiscal 2008 second quarter,results for the ... market closes. Senior management will host a live webcast and,conference call ... Time., What: Plexus Corp.,s ... Thursday, April 24th at 8:30 a.m. Eastern Time, ...
... Germany, April 24, 2008 / b3c newswire / ... Stanford University are working on a project to synthesize ... in a statistically expected and controlled ratio at preselected ... utilize its core technology, Slonomics™, a unique DNA engineering ...
Cached Biology Technology:Plexus Q2 Earnings Release on April 23rd After Market Close and Conference Call on April 24th at 8:30 am E.T. 2Sloning and the Kornberg group at Stanford University starting evaluation project regarding the synthesis of a Statistically Randomized Gene Library 2
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, reminds investors ... Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA ... 5-7, 2015. The three-day conference is organized ... is speaking in is themed Global Fraud: Where is ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/13/2015)... YORK , April 13, 2015 ... by TechSci Research, "Global Biometrics Market Forecast & Opportunities, ... register a CAGR of around 14% till 2020. ... governments for large scale implementation and review of ... and launch of new products with greater efficiency, ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... Engineering researchers the University of Southern California have made ... the construction of a synthetic brain. They have built ... reproduces the function of a neuron, the building block ... by Professor Alice Parker and Professor Chongwu Zhou in ...
... rearrangements in roundworm chromosomes may offer new insight into large-scale ... of the research led by University of North Carolina at ... April 22 online edition of the journal Science . ... sequence that protects the ends of chromosomes from deterioration or ...
... how a single-celled fungus survives in low-oxygen settings may ... organ transplants or AIDS. A report on the ... 22 in Molecular Cell . Previous work ... model organism that,s often used to study individual genes, ...
Cached Biology News:Researchers create functioning synapse using carbon nanotubes 2Study in roundworm chromosomes may offer new clues to tumor genome development 2Simple fungus reveals clue to immune system protection 2
With sodium bicarbonate. Sterile, Cell culture tested...
... Easy and Cost effective - Utilizes hands-off homogenization ... , No grinding - Extract DNA without ... tools between samples , Robust tubes ... and homogenize without tube breakage , ...
Imject Freund's Complete Adjuvant (FCA)...
The Synergy HT utilizes a unique dual-optics design combined with monochromator wavelength selection to provide uncompromised performance in absorbance, fluorescence and luminescence reading modes. ...
Biology Products: